Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Benevolo

Showing results (61-70 of 123) with videos related to

Pageof 13
Sort By:
Blood|January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaValeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
Leukemia Research|May 8, 2018
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemiaBarbara Mora, Toni Giorgino, Paola Guglielmelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
Blood Advances|February 12, 2026
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian studyFrancesco Autore, Alessandra Tedeschi, Giulia Benevolo, et al.
Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
Blood Advances|June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with RuxolitinibFrancesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
Blood Cancer Journal|October 7, 2018
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC projectDaniela Barraco, Barbara Mora, Paola Guglielmelli, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
The Lancet. Haematology|August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trialSara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.
Pageof 13

Showing results (61-70 of 123) with videos related to

Sort By:
Pageof 13
Blood|January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaValeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
Leukemia Research|May 8, 2018
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemiaBarbara Mora, Toni Giorgino, Paola Guglielmelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
Blood Advances|February 12, 2026
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian studyFrancesco Autore, Alessandra Tedeschi, Giulia Benevolo, et al.
Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
Blood Advances|June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with RuxolitinibFrancesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
Blood Cancer Journal|October 7, 2018
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC projectDaniela Barraco, Barbara Mora, Paola Guglielmelli, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
The Lancet. Haematology|August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trialSara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.
Pageof 13